Mortality Risk Factors of COVID-19 Infection in Kidney Transplantation Recipients: A Systematic Review and Meta-Analysis of Cohorts and Clinical Registries

Suwasin Udomkarnjananun, MD,^{1,2,3} Stephen J. Kerr, PhD,^{4,5} Natavudh Townamchai, MD,^{1,2,3} Paweena Susantitaphong, MD, PhD,¹ Wasee Tulvatana, MD,⁶ Kearkiat Praditpornsilpa, MD,¹ Somchai Eiam-Ong, MD,¹ Yingyos Avihingsanon, MD^{1,2,3}

¹Division of Nephrology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand

²Renal Immunology and Transplantation Research Unit, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

³Excellence Center for Solid Organ Transplantation, King Chulalongkorn Memorial Hospital, Bangkok, Thailand

⁴Research Affairs, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

⁵The Kirby Institute, University of New South Wales, Sydney, NSW, Australia


⁶Department of Ophthalmology, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand

Correspondence: Suwasin Udomkarnjananun, Division of Nephrology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, 1873 Rama IV Road, Bangkok, Thailand,10330.

Supplementary Table S1: Quality assessment of the included studies using the Newcastle-Ottawa Quality Assessment Scale.

Authors	Selection	Comparability	Outcome			
	(From total of $\bullet \bullet \bullet \bullet$)	(From total of $\bullet \bullet$)	(From total of $\bullet \bullet \bullet$)			
Bossini et al.	••••	••	••			
Cravedi et al.	••••	••	•••			
Caillard et al.	••••	••	•••			
Azzi et al.	••••	••	•••			
Craig-Schapiro et al.	••••	••	•••			
Hilbrands et al.	••••	••	•••			
Mamode et al.	••••	••	••			
Willicombe et al.	••••	••	••			
Oto et al.	••••	••	•••			
Kute et al.	••••	••	•••			
Villanego et al.	••••	••	•••			
Alshaqaq et al.	••••	••	••			
Requiao-Moura et al.	••••	••	••			


Supplementary Figure S1: Forest plot of patient characteristics that were significantly associated with mortality.





D		es melli	tus		Odds ra with 95%	Weight (%)	
Cravedi et al.					1.14 [0.57,	2.31]	10.26
Caillard et al.	-				2.18 [1.12,	4.25]	11.38
Azzi et al.	-				2.45 [1.18,	5.13]	9.35
Craig-Schapiro et al.	-	-			-3.60 [0.97,	13.32]	2.99
Hilbrands et al.	-	-	-		2.08 [1.18,	3.66]	15.74
Mamode et al.			-		1.47 [0.67,	3.23]	8.27
Willicombe et al.	-				- 3.84 [1.17,	12.63]	3.61
Oto et al.					2.32 [0.55,	9.73]	2.49
Kute et al.	-	-			2.03 [0.91,	4.51]	7.98
Villanego et al.	-1	-			1.37 [0.90,	2.08]	27.94
Overall		+			1.80 [1.43,	2.25]	
Heterogeneity: $r^2 = 0.00$, $I^2 = 1.49\%$, $H^2 = 1.02$	_	1					
	1	2	4	8			
Random-effects REML model Surviv	ors	Non-su	rvivors				


Study	Cardiovascular disease						Odds ratio with 95% CI		
Cravedi et al.		-	-	-		1	2.10 [0.99,	4.46]	15.12
Caillard et al.			-	-			2.50 [1.28,	4.90]	18.24
Azzi et al.	-	-	+				1.16 [0.54,	2.49]	14.81
Craig-Schapiro et al.	-			-			1.37 [0.39,	4.87]	6.08
Hilbrands et al.			-		- 1	į	3.26 [1.84,	5.78]	23.15
Willicombe et al.	_	-	-		-		1.81 [0.56,	5.77]	7.13
Oto et al.			+	-	-		5.33 [1.63,	17.42]	6.89
Kute et al.		-					1.63 [0.57,	4.67]	8.57
Overall Heterogeneity: $\tau^2 = 0.03$, $I^2 = 15.26\%$, $H^2 = 1.18$	1/2	_	2	•	8	16	2.21 [1.60,	3.06]	
Random-effects REML model Si	1/2 urvivors	1		4 survivo		16			


Study	4	ctive c	ncer		Odds ratio with 95% CI		
Cravedi et al.		-	-		1.99 [0.79,	5.02]	22.88
Caillard et al.		-			1.19 [0.48,	2.95]	23.41
Azzi et al.		-			1.08 [0.38,	3.09]	20.18
Hilbrands et al.					4.69 [1.89,	11.60]	23.33
Willicombe et al.		-			2.67 [1.08,	148.48]	5.88
Oto et al.		-	-		0.47 [0.03,	8.89]	4.32
Overall Heterogeneity: τ^2 = 0.25, I^2 = 41.22%, H^2 = 1.70		-			2.00 [1.05,	3.80]	
	/32	1/2	8	128			
Random-effects REML model	Surviv	ors	Non-surv	ivors			














Supplementary Figure S2: Forest plot of laboratory investigations that were significantly associated with mortality.





Study	C-reactive protein				Mean diff. with 95% CI		
Cravedi et al.				2.40 [-0.71,	5.51]	22.34
Azzi et al.			-	2.80 [-1.13,	6.73]	20.40
Craig-Schapiro et al		-		-0.50 [-12.94,	11.94]	6.56
Hilbrands et al.		-		4.30 [2.52,	6.08]	25.05
Kute et al.			-	10.50 [9.13,	11.87]	25.66
Overall Heterogeneity: r^2 = 13.17, l^2 = 88.93%, H^2 = 9.03		-	-	4.85 [1.18,	8.52]	
	-10	0	10				
Random-effects REML model	Survivor	No No	n-survivo	ors			



Supplementary Figure S3: Forest plot of treatments received that were significantly associated with mortality.

